Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Increased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 20.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,369,302 shares of the company's stock after acquiring an additional 405,741 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.21% of Teva Pharmaceutical Industries worth $52,219,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. UMB Bank n.a. grew its holdings in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after buying an additional 2,067 shares during the last quarter. Smithfield Trust Co grew its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $52,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $60,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average target price of $23.57.

Teva Pharmaceutical Industries Stock Down 2.4 %

NYSE TEVA traded down $0.40 on Friday, hitting $16.24. 12,463,268 shares of the stock traded hands, compared to its average volume of 12,918,501. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97. The stock has a 50-day moving average of $19.98 and a 200 day moving average of $18.49. The company has a market capitalization of $18.39 billion, a P/E ratio of -11.20, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company's stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.